All In Biotech

Drug Trial Radar · NCT04929223

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 542 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

542

Planned (sponsor's estimate)

Start

Oct 22, 2021

Primary completion

Aug 31, 2030

Study completion Aug 31, 2030

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • InavolisibDrug

    Inavolisib will be administered orally as per schedule specified in the respective arms.

  • BevacizumabDrug

    Bevacizumab IV will be administered as per schedule specified in the respective arm.

  • CetuximabDrug

    Cetuximab IV will be administered as per schedule specified in the respective arm.

  • AtezolizumabDrug

    Atezolizumab IV infusion will be administered as per schedule specified in the respective arm.

  • TiragolumabDrug

    Tiragolumab IV infusion will be administered as per schedule specified in the respective arm.

  • SY-5609Drug

    SY-5609 will be administered by mouth as per schedule specified in the respective arm.

  • DivarasibDrug

    Divarasib will be administered orally as per schedule specified in the respective arms.

  • FOLFOXDrug

    FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) IV will be administered as per schedule specified in the respective arm.

  • FOLFIRIDrug

    FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) IV will be administered as per schedule specified in the respective arm.

  • FoundationOne®Liquid CDxDiagnostic test

    FoundationOne®Liquid CDx is used to identify presence of genomic alterations for participant cohort assignment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: Approximately 84 months

Locations

84 sites in 11 countries. Site status is shown where the registry gives one.

  • UAB Comprehensive Cancer Center

    Birmingham, Alabama · Withdrawn

  • Mayo Clinic Arizona

    Phoenix, Arizona · Active not recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • cCare

    Encinitas, California · Withdrawn

  • USC Norris Cancer Center

    Los Angeles, California · Completed

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UCLA

    Los Angeles, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Withdrawn

  • Stanford Cancer Center

    Stanford, California · Completed

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • Rocky Mountain Cancer Centers, LLP

    Lone Tree, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Eastern Ct Hema/Onco Assoc

    Norwich, Connecticut · Withdrawn

  • Mayo Clinic in Florida

    Jacksonville, Florida · Completed

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Illinois Cancer Specialists

    Arlington Heights, Illinois · Recruiting

  • Mary Bird Perkins Cancer Ctr

    Baton Rouge, Louisiana · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Completed

  • Karmanos Cancer Institute

    Detroit, Michigan · Withdrawn

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • New York Cancer & Blood Specialists - New Hyde Park

    New Hyde Park, New York · Recruiting

  • New York Cancer and Blood Specialists-Central Park Hematology & Oncology

    New York, New York · Recruiting

  • New York Cancer & Blood Specialists

    Port Jefferson Station, New York · Recruiting

  • New York Cancer & Blood Specialists - Bronx

    The Bronx, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Completed

  • Hematology Oncology Salem

    Salem, Oregon · Completed

  • UPMC - Hillman Cancer Center

    Pittsburgh, Pennsylvania · Active not recruiting

  • Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee · Completed

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Completed

  • Texas Oncology - Northeast Texas

    Denton, Texas · Recruiting

  • Lumi Research

    Kingwood, Texas · Withdrawn

  • Texas Oncology - Gulf Coast

    Webster, Texas · Recruiting

  • Swedish Cancer Inst.

    Seattle, Washington · Completed

  • Medical Oncology Associates

    Spokane, Washington · Withdrawn

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Active not recruiting

  • Jewish General Hospital

    Montreal, Quebec, Canada · Withdrawn

  • McGill University Health Center

    Montreal, Quebec, Canada · Withdrawn

  • Herlev Hospital, Afdeling for Kræftbehandling, Center for Kræftforskning, Klinisk Forskningsenhed

    Herlev, Denmark · Recruiting

Showing 40 of 84 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.